RBL LLC welcomes James Watson to board of directors

Experienced biotech executive joins board to support RBL's venture creation and growth strategy

HOUSTON, June 17, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies from Rice University, announced the appointment of James Watson to its board of directors. Watson, an operating partner at Andreessen Horowitz and a seasoned executive in the life sciences sector, brings to RBL LLC extensive experience in business strategy, corporate development and venture-backed company building, strengthening the organization's mission to accelerate lifesaving therapies from lab to clinic.

"The appointment of James Watson to our board reflects a powerful endorsement of RBL's model and potential," said Paul Wotton, RBL's managing partner. "James has occupied high-level positions across the full life cycle of biotech innovation, from company formation and financing to the construction of valuable partnerships in this field. His insights into market dynamics and his ability to drive successful outcomes for emerging ventures such as ours will be critical as we continue to grow."

"James' leadership spans both operational roles within biotech companies and strategic roles at one of the world's top venture firms," said Omid Veiseh, Rice professor of bioengineering and managing partner of RBL. "His ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups."

"RBL is approaching company creation in an innovative and differentiated way, with a positive impact that is starting to be seen across the broader Houston life sciences community," Watson said. "RBL has distinguished itself through its efficient approach to company formation, identifying substantive technologies with clear clinical applications and establishing focused enterprises to advance them. I was also particularly drawn to the strategic positioning of the studio in Houston, where it operates at the intersection of world-class academic research, clinical scale and entrepreneurial rigor, all fundamental components of building a successful scientific venture."

Watson is currently serving as operating partner on the Bio + Health team at Andreessen Horowitz, where he leads business and corporate development for the firm's life sciences portfolio. Prior to joining Andreessen Horowitz, he held executive positions at numerous biotech companies, including Carmot Therapeutics, where as chief business officer, he was head of strategy, finance and corporate development. At Carmot, Watson led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that significantly contributed to Carmot's $2.7 billion acquisition by Roche. Notably, he also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly. Earlier in his career, Watson served as CEO of merchant banking at Burrill & Company, a life sciences investment bank, and held leadership roles at Alvine Pharmaceuticals, Incyte, Chemdex, The Wilkerson Group and Eli Lilly. He earned an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth.

Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith and Paul Cherukuri, an accomplished group of leaders with deep expertise in biotech innovation, clinical translation and venture building who together provide strategic guidance to help drive RBL's continued growth and success.

About RBL LLC:

RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit https://www.rbl-llc.com/.

Media Contact:

Russo Partners
David Schull or Liz Phillips
(347) 956-7697
[email protected]
[email protected]

SOURCE RBL LLC